Applikon to buy HaloteC’s biotech portfolio
Bioreactor systems vendor Applikon Biotechnology has arranged to acquire the biotech portfolio of Dutch instruments and software provider HaloteC Instruments.
Applikon CEO Arthur Oudshoorn said the company plans to use the HaloteC technology to augment its existing its bioreactor software offerings.
“Organisations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes,” he said.
Oudshoorn added that the investment forms part of Applikon’s efforts to be able to provide an advanced data centre for biotech processes.
Terms of the transaction were not disclosed.
Applikon Biotechnology is headquartered in the Netherlands and in Belgium. In Australia and New Zealand, the company provides its products through its dedicated agent Enztech in New South Wales.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
